Intensity Therapeutics

Intensity Therapeutics is a late-stage clinical biotechnology company developing intratumoral cancer therapies designed to address both the regional and systemic nature of cancer relapse and metastasis. Its lead product candidate, INT230-6, combines active anti-cancer agents with amphiphilic molecules using the company's proprietary DfuseRx non-covalent conjugation technology; it is in Phase 3 clinical studies for soft tissue sarcoma and in Phase 2 trials for neoadjuvant and metastatic triple-negative breast cancer. Incorporated in 2012, the company is headquartered in Shelton, Connecticut and listed on Nasdaq in June 2023.